{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:29:41Z","timestamp":1787905781433,"version":"build-2784847793"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck & Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.diagmicrobio.2018.05.011","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T12:38:20Z","timestamp":1526647100000},"page":"158-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013\u20132015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program"],"prefix":"10.1016","volume":"92","author":[{"given":"Dee","family":"Shortridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0005","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/INF.0000000000001228","article-title":"Use of ceftolozane\/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient","volume":"35","author":"Aitken","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1080\/21505594.2015.1134072","article-title":"Bloodstream infections in the intensive care unit","volume":"7","author":"Bassetti","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0015","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/jac\/dkx146","article-title":"Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype","volume":"72","author":"Bevan","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0020","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.02462-13","article-title":"Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC","volume":"58","author":"Cabot","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0025","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1128\/AAC.02252-12","article-title":"Prevalence of beta-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY antimicrobial surveillance program (2010)","volume":"57","author":"Castanheira","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0030","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1128\/AAC.00540-16","article-title":"Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates","volume":"60","author":"Castanheira","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0035","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1089\/mdr.2015.0220","article-title":"Multidrug-resistant gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options","volume":"22","author":"Cerceo","year":"2016","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0040","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard- tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0045","series-title":"M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0050","series-title":"European Committee on Antimicrobial Susceptibility Testing","article-title":"Breakpoint tables for interpretation of MIC's and zone diameters. Version 7.1, March 2017","author":"EUCAST","year":"2017"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0055","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ijantimicag.2014.01.032","article-title":"Ceftolozane\/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012)","volume":"43","author":"Farrell","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0060","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jac\/dkx424","article-title":"Mechanisms leading to in vivo ceftolozane\/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa","volume":"73","author":"Fraile-Ribot","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0065","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1378\/chest.09-0087","article-title":"Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock","volume":"136","author":"Kumar","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0070","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/jac\/dkx136","article-title":"Activity of ceftolozane\/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British isles","volume":"72","author":"Livermore","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0075","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0080","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40121-016-0104-3","article-title":"Successful treatment of multi-drug resistant Pseudomonas aeruginosa bacteremia with the recommended renally adjusted ceftolozane\/Tazobactam regimen","volume":"5","author":"Patel","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0085","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0090","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1128\/AAC.01737-10","article-title":"Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes","volume":"55","author":"Sader","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0095","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa1703058","article-title":"Time to treatment and mortality during mandated emergency Care for Sepsis","volume":"376","author":"Seymour","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/joim.12342","article-title":"Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control","volume":"277","author":"Tangden","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0110","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1128\/AAC.01509-06","article-title":"Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment","volume":"51","author":"Tumbarello","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0115","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0120","series-title":"wwwpfizermedicalinformationcom","article-title":"Tygacil (tigecycline) Prescribing information","author":"Wyeth Pharmaceuticals, I","year":"2010"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0125","series-title":"ZERBAXA\u00ae (ceftolozane\/tazobactam)","author":"ZERBAXA","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2018.05.011_bb0130","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s13054-014-0596-8","article-title":"Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in gram-negative severe sepsis and septic shock: a retrospective cohort study","volume":"18","author":"Zilberberg","year":"2014","journal-title":"Crit Care"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889318301688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T15:16:28Z","timestamp":1536246988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889318301688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0732889318301688"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.05.011","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa collected from patients with bloodstream infections isolated in United States hospitals (2013\u20132015) as part of the Program to Assess Ceftolozane-Tazobactam Susceptibility (PACTS) surveillance program","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}